Immune Thrombocytopenia (ITP) in a Patient with Relapsing-Remitting Multiple Sclerosis (RRMS) Associated with b-Interferon-1α Treatment
Vahid Shaygannejad1,2, Emad Fayyazi1,3, Omid Mirmosayyeb1,3, Nafiseh Toghianifar1,4★★ Corresponding author
- 1Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, IRAN.
- 2Department of Neurology, Isfahan University of Medical Sciences, Isfahan, IRAN.
- 3Medical students’ research Committee, Isfahan University of Medical Sciences, Isfahan, IRAN.
- 4Non-communicable Disease Unit, Vice Chancellor for Clinical Affairs, Isfahan University of Medical Sciences, Isfahan, IRAN.
CORRESPONDENCE
Nafiseh Toghianifar
Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, IRAN.
Received: 29-09-2017; Revised: 08-11-2017; Accepted: 15-12-2017.
Volume 52, Issue 3 · pp. 540–542 · PUBLISHED 2018 · DOI: 10.5530/ijper.52.3.62
ABSTRACT
Immune thrombocytopenia is an isolated thrombocytopenia not related to other etiologies of thrombocytopenia.1 The diagnosis relies mainly on exclusion of other conditions.2,3 The incidence of ITP among adults has been estimated to be 3.3 per 100,000 persons in Europe according to a review study in 2009.4 ITP may be induced by drugs.2 In this type of ITP, a drug induces production of antibodies against platelets and causes destruction and reduction of platelets.2 This is usually transient and improves after withdrawal of the offending drug.1,2
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Shaygannejad, V., Fayyazi, E., Mirmosayyeb, O., & Toghianifar, N. (2018). Immune Thrombocytopenia (ITP) in a Patient with Relapsing-Remitting Multiple Sclerosis (RRMS) Associated with b-Interferon-1α Treatment. Indian Journal of Pharmaceutical Education and Research, 52(3), 540–542. https://doi.org/10.5530/ijper.52.3.62